Top > Search of International Patents > ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS

ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS meetings

Foreign code F180009460
File No. (S2017-0054-N0)
Posted date Jul 31, 2018
Country WIPO
International application number 2017JP037624
International publication number WO 2018074497
Date of international filing Oct 18, 2017
Date of international publication Apr 26, 2018
Priority data
  • P2016-204783 (Oct 19, 2016) JP
Title ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS meetings
Abstract Disclosed is a novel means making it possible to suppress the formation of atherosclerotic lesions and treat arteriosclerosis. The anti-atherosclerotic agent according to the present invention comprises, as an active ingredient, a substance for selectively suppressing B2 cells. The substance for selectively suppressing B2 cells is for example an anti-CD23 antibody. A first embodiment of a method for assisting the identification of arteriosclerosis symptoms of the present application comprises using a sample isolated from a subject to measure the expression of at least one gene selected from a specific gene group. A second embodiment of the method comprises measuring the IgG3 level or total IgG level in a serum sample isolated from a subject.
Outline of related art and contending technology BACKGROUND ART
Arteriosclerosis is a lifestyle-related disease in a final image. Diabetes, hypertension, dyslipidemia, chronic kidney disease, risk factors such as smoking (non-patent document 1) can be controlled, to control the accuracy of the onset of the present invention, such as catastrophe of the acute disease (myocardial infarction, cerebral infarction, the severity of the lower limb ischemia) is exhibited, the medical resource (fire emergency system, acute vessel-treated can be acute hospital personnel and equipment to a) maximize the use of the, in addition to the method of the regulator is not a rescue. Risk control strategy, the reliability is poor, also in clinical trials, and test subject population, with the risk relative to the effectiveness of the only.
The genesis of the present invention, the high-risk state as well as lifestyle-related diseases, inflammation, immune responses are considered to be derived from the disease. The inventors of the present invention, so far, such as serum molecule IL-5 autoantibodies involved in atherosclerosis has been reported (Non-Patent Document 2, Patent Document 1). However, readout of the arteriosclerosis genesis aggressive treatment means has not been developed yet.
Is Patent Document 2, an anti-CD20 antibody and B by the depleted treating atherosclerotic prevention that the invention is not disclosed. CD20 Is, peripheral blood or lymphoid organs 90% of the cell B of the surface of greater than 35kDa of the non-glycosylated phosphoprotein found and, between the occurrence of an initial pre-B cell expression, differentiation of transformed cells (Patent Document 2) to last. That is, when the anti-CD20 antibody, the target and the B cells generally, it is possible to reduce the number of the cells are assumed.
Scope of claims (In Japanese)[請求項1]
B2細胞を選択的に抑制する物質を有効成分とする、抗動脈硬化剤。
[請求項2]
B2細胞を選択的に抑制する物質が抗CD23抗体である、請求項1記載の抗動脈硬化剤。
[請求項3]
被検者から分離された試料を用いて、以下の遺伝子群A及び遺伝子群Bからなる群より選択される少なくとも1つの遺伝子の発現を測定することを含む、動脈硬化の病態の判定を補助する方法。
遺伝子群A:
Ccl2、Cd14、Hspa1a、Il1b、Il1r1、Ptgs2、Tnfrsf1a、Tlr5
遺伝子群B:
Cebpb、Fos、Jun、Nfkbib、Chuk、Ikbkb、Irf1、Mapk8、Mapk8ip3、Mapk9、Tollip、Tradd
[請求項4]
前記被検者が動脈硬化症患者である、請求項3記載の方法。
[請求項5]
前記試料がB2細胞を含む試料である、請求項3又は4記載の方法。
[請求項6]
前記遺伝子群Aは、高発現が動脈硬化の存在又は悪化の指標となる遺伝子であり、前記遺伝子群Bは、低発現が動脈硬化の存在又は悪化の指標となる遺伝子である、請求項3ないし5のいずれか1項に記載の方法。
[請求項7]
被検者から分離された血清試料中のIgG3レベル又は総IgGレベルを測定することを含む、動脈硬化の病態の判定を補助する方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • YOKOHAMA CITY UNIVERSITY
  • Inventor
  • ISHIGAMI, Tomoaki
  • CHEN, Lin
IPC(International Patent Classification)
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close